Literature DB >> 10656427

Effects of the polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaundecane and N1-ethylN-11-((cycloheptyl)methyl)-4,8-diazaundecane in human prostate cancer cells.

D E McCloskey1, P M Woster, R A Casero, N E Davidson.   

Abstract

The high levels of polyamines maintained in the prostate suggest that these compounds are important to prostate cell function and that disruption of polyamine metabolism may be an effective way to stop the growth of prostate cancer cells. The unsymmetrically alkylated polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaunde-cane (CPENSpm) and N1-ethyl-N11-((cycloheptyl)methyl)-4,8-diazaundecane (CHENSpm) have been shown previously to have cytotoxic effects in breast and non-small cell lung cancer cells. We have now investigated the responses of three human prostate cancer cell lines, LNCaP, PC3, and Du145, to these polyamine analogues and to the symmetrically alkylated analogue N1,N11-bis(ethyl)norspermine (BE 3-3-3). The Du145 cell line, in which IC50 values ranged from 0.65 to 0.8 microM, was the most sensitive to each of the polyamine analogues, although significant growth inhibition resulted in the other cell lines as well. CPENSpm and BE 3-3-3 but not CHENSpm caused significant decreases in the intracellular spermine and spermidine pools, although all three analogues accumulated to high levels in each of the cell lines. Spermidine/spermine N1-acetyltransferase activity was induced 23-250-fold in response to CPENSpm and BE 3-3-3, but it was not affected by CHENSpm. None of the analogues had significant effects on the activities of ornithine decarboxylase or S-adenosylmethionine decarboxylase. Quantitation of DNA fragmentation indicative of programmed cell death (PCD) showed that both CPENSpm and CHENSpm were effective inducers of PCD in all three prostate cell lines. In contrast, BE 3-3-3 led to PCD only in LNCaP cells. The ability to induce PCD was the only parameter measured that correlated with cell line sensitivity to these polyamine analogues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656427

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  The synthesis of deuterium-labeled spermine, N-acetylspermine and N-acetylspermidine.

Authors:  Vijay Gawandi; Paul F Fitzpatrick
Journal:  J Labelled Comp Radiopharm       Date:  2007-06-01       Impact factor: 1.921

Review 2.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 3.  Inhibition of diamine oxidases and polyamine oxidases by diamine-based compounds.

Authors:  M Sebela; M Tylichová; P Pec
Journal:  J Neural Transm (Vienna)       Date:  2007-03-26       Impact factor: 3.575

Review 4.  Design of polyamine-based therapeutic agents: new targets and new directions.

Authors:  M D Thulani Senanayake; Hemali Amunugama; Tracey D Boncher; Robert A Casero; Patrick M Woster
Journal:  Essays Biochem       Date:  2009-11-04       Impact factor: 8.000

5.  Spermine analogue-regulated expression of spermidine/spermine N1-acetyltransferase and its effects on depletion of intracellular polyamine pools in mouse fetal fibroblasts.

Authors:  Anne Uimari; Tuomo A Keinänen; Anne Karppinen; Patrick Woster; Pekka Uimari; Juhani Jänne; Leena Alhonen
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

Review 6.  Oncology Therapeutics Targeting the Metabolism of Amino Acids.

Authors:  Nefertiti Muhammad; Hyun Min Lee; Jiyeon Kim
Journal:  Cells       Date:  2020-08-15       Impact factor: 6.600

7.  Increased breast cancer cell toxicity by palladination of the polyamine analogue N (1),N (11)-bis(ethyl)norspermine.

Authors:  Tania M Silva; Sonia M Fiuza; Maria P M Marques; Lo Persson; Stina Oredsson
Journal:  Amino Acids       Date:  2013-12-21       Impact factor: 3.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.